SIRTURO (bedaquiline fumarate)
DIARYLQUINOLINE ANTI-MYCOBACTERIAL ANTIBIOTICS · PULMONARY MULTI-DRUG RESISTANT MYCOBACTERIUM TUBERCULOSIS
JANSSEN PRODUCT
Drug class
Diarylquinoline Anti-Mycobacterial Antibiotics
Diarylquinoline anti-mycobacterial antibiotics are a targeted class of antibacterial agents characterized by a central quinoline core substituted with aryl moieties. Read more about Diarylquinoline Anti-Mycobacterial Antibiotics
1 drugs in this class 1 manufacturers
Drugs in Diarylquinoline Anti-Mycobacterial Antibiotics
Filter & compare in the drug finder →
Opens the drug finder with Diarylquinoline Anti-Mycobacterial Antibiotics preselected. Add indication or manufacturer filters there.
Diarylquinoline anti-mycobacterial antibiotics are a targeted class of antibacterial agents characterized by a central quinoline core substituted with aryl moieties.
They exert their therapeutic bactericidal effect by selectively binding to subunit c of mycobacterial adenosine triphosphate (ATP) synthase, shutting down cellular energy production in dormant and replicating bacilli.
Clinically represented by bedaquiline, this class is primarily utilized as part of combination therapy to treat pulmonary multi-drug resistant tuberculosis (MDR-TB).
-
wikipedia.org
Diarylquinoline anti-mycobacterial antibiotics are a targeted class of antibacterial agents characterized by a central quinoline core substituted with aryl moieties
-
medpath.com
Diarylquinoline anti-mycobacterial antibiotics are a targeted class of antibacterial agents characterized by a central quinoline core substituted with aryl moieties Clinically represented by bedaquiline, this class is primarily utilized as part of combination therapy to treat pulmonary multi-drug resistant tuberculosis (MDR-TB)
-
drugs.com
They exert their therapeutic bactericidal effect by selectively binding to subunit c of mycobacterial adenosine triphosphate (ATP) synthase, shutting down cellular energy production in dormant and replicating bacilli Clinically represented by bedaquiline, this class is primarily utilized as part of combination therapy to treat pulmonary multi-drug resistant tuberculosis (MDR-TB)
-
nih.gov
They exert their therapeutic bactericidal effect by selectively binding to subunit c of mycobacterial adenosine triphosphate (ATP) synthase, shutting down cellular energy production in dormant and replicating bacilli
-
nih.gov
They exert their therapeutic bactericidal effect by selectively binding to subunit c of mycobacterial adenosine triphosphate (ATP) synthase, shutting down cellular energy production in dormant and replicating bacilli
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.